By Ellen Capon (Drug Target Review)2024-05-28T10:00:45
In this Q&A, Celularity’s CEO and founder Dr Robert Hariri details the preclinical research that indicates that placenta-derived unmodified NK cells and genetically modified NK cells can target and selectively eliminate cells expressing stress ligands.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-04-13T10:14:00Z
2025-06-11T14:00:00
Sponsored by Eurofins Discovery
2026-06-02T15:00:00 2026-06-02T16:00:00
Sponsored by Danaher Life Sciences
2025-10-22T14:00:00
Sponsored by Wuxi Biologics
2024-01-26T13:22:42
Sponsored by bit.bio
2024-02-07T14:34:33
Sponsored by BellBrook Labs
2025-09-18T12:00:00
Sponsored by Benchling
Site powered by Webvision Cloud